27-10-2010: Algeta ASA announced it has entered into a technology access agreement with Lumiphore, Inc. that could enable Algeta to develop the next generation of cancer-targeting alpha-pharmaceuticals. The agreement provides Algeta with exclusive access to Lumiphore’s novel, patented Lumi4® chelator technology, which will be evaluated for its ability to bind the alpha-emitter thorium-227 and link it to tumor-targeting molecules, such as antibodies.
Algeta’s strategy for enhancing its alpha-pharmaceutical pipeline beyond Alpharadin, which is currently in phase III, is focused initially on the development of a robust proprietary position around its Thorium platform through both in-house development and selective in-licensing.
The ability to link the alpha-emitter thorium-227 to tumor-targeting molecules is crucial for the development of these new alpha-pharmaceuticals. Algeta has significant chelation expertise having already demonstrated the potent tumor-cell killing capability of thorium-227-conjugated monoclonal antibodies using non-proprietary chelators in validated preclinical models for breast cancer and lymphoma cells.
Lumiphore’s Lumi4® isophthalamide technology is based on a new class of chelators that bind metals in the lanthanide and actinide groups of the periodic table – thorium is an actinide. The primary benefit of the technology as it relates to Algeta’s Thorium platform is that it forms a novel cage structure surrounding and tightly binding thorium, which can then be covalently attached to a range of tumor-targeting molecules.
Algeta believes that access to the Lumi4® technology offers a number of potential advantages that could produce enhanced conjugates when compared to those successfully employed in the previous thorium feasibility studies. Key benefits are expected to include more rapid, efficient and cost-effective chelation and conjugation processes, and increased conjugate stability. In addition, use of the technology if applied successfully, is anticipated to strengthen Algeta’s proprietary position around its Thorium platform.
Under the terms of the agreement, Algeta obtains an exclusive 12-month option to an exclusive license for the use of Lumiphore’s Lumi4® chelator technology within the field of therapeutic radiopharmaceuticals. The license will also give Algeta the right to use this technology in companion imaging radiopharmaceuticals for determining either the suitability of patients for treatment and/or the effectiveness of treatment.
Algeta will pay Lumiphore a fee on signing the option agreement and will make further payments should it exercise the option and take up the license.
Algeta ASA announced it has entered into a technology access agreement with Lumiphore, Inc. that could enable Algeta to develop the next generation of cancer-targeting alpha-pharmaceuticals. The agreement provides Algeta with exclusive access to Lumiphore’s novel, patented Lumi4® chelator ... more
Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specif ... more
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Algeta ASA celebrated the official opening of the offices and facilities of Algeta US in Cambridge, Massachusetts.In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of Alpharadin. Under the terms of the agreement, Bayer will develop, apply for ... more
Cobra Biologics Ltd and Algeta ASA announced a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program. The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target ... more
Algeta is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer.
The Company is targeting metastatic and disseminated tumor types for which there is substantial unmet medical need.
Its first product candi ... more